Search Results

You are looking at 31 - 40 of 899 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff

limited metastases is not yet known. Role of Chemotherapy in Metastatic PCA In 1996, weekly doses of gemcitabine proved to be modestly superior to weekly bolus fluorouracil. Furthermore, clinical benefit, an end point not commonly used in subsequent

Full access

Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases

Jacqueline Jonklaas

treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma . J Clin Endocrinol Metab 1986 ; 63 : 960 – 967 . 32. Liel Y . Preparation for radioactive iodine administration in differentiated thyroid cancer

Full access

CLO20-040: Factors Influencing Survival of Patients Treated for Spinal Metastases at a Regional Cancer Center in Appalachia

Hassaan Raza Jafri, Isna Batool Khan, Ahmad Abu-Hashyeh, Vivek Yadala, Hassaan Yasin, Todd Gress, and Maria Tirona

Background: Most patients with spinal metastases have limited survival. This study sought to analyze the factors associated with survival of patients treated for spinal metastases at our institution. Treatment modalities included steroids

Full access

Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy

William R. Kennedy, Christopher Tricarico, Prashant Gabani, Ashley A. Weiner, Michael B. Altman, Laura L. Ochoa, Maria A. Thomas, Julie A. Margenthaler, Souzan Sanati, Lindsay L. Peterson, Cynthia X. Ma, Foluso O. Ademuyiwa, and Imran Zoberi

context of all breast cancers, with most studies not reporting subgroup data for patients with TNBC. Some groups have reported a greater probability of nodal metastases and relapse and worse survival in multifocal tumors, but these associations have been

Full access

Initial Management and Follow-up of Differentiated Thyroid Cancer in Children

Steven G. Waguespack and Gary Francis

metastasizes to regional neck lymph nodes. Hematogenous metastases are much less common and generally occur only with significant regional lymph node metastases. 10 , 15 FTC is typically a unifocal tumor and more prone to initial hematogenous metastases to

Full access

Differential Radiographic Appearance of BRAF V600E–Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location

Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr

, and/or a distinct pattern of metastatic spread. 19 , 23 At diagnosis of mCRC, Yaeger et al 23 found that BRAF -mutated tumors were associated with more frequent peritoneal metastases (26% vs 14%; P <.01) and less frequent liver-limited metastases

Full access

EPR24-114: Analysis of Risk of Bone Fracture and Osteoporosis and Dual-Energy X-Ray Absorptiometry Screening Rates in Lung Cancer Survivors With and Without Bone Metastases

Ilene Trinh, Jaime Abraham Perez, Elleson Harper, Lauren Chiec, Qian Wang, and Melinda Hsu

studies on fracture risk in lung cancer survivors (LCS) with mixed results. Up to 40% of patients with advanced lung cancer develop bone metastases. Among LCS without bone metastasis, screening rates for osteoporosis utilizing dual-energy X

Full access

YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases

Richard Tobin, Elizabeth N. Katsnelson, Kasey L. Couts, Andrea Spengler, Liyen Loh, Laurent Gapin, and Martin D. McCarter

gastrointestinal (GI) metastases of cutaneous melanomas (CM-GIM). MAIT cells are activated by non-peptide antigens and accumulate in mucosal sites. Therefore, we sought to compare the frequency and activation of anatomically similar MM and CM-GIM. We hypothesize

Full access

Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging?

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

excluded if they had known evidence of lung, liver, bone, or brain metastases; previous treatment with RT or chemotherapy was unknown; they received brachytherapy alone; or they had documented RT to a nonpelvic site. Patients diagnosed or treated at a

Full access

Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location

Angela Jain, Paula D. Ryan, and Michael V. Seiden

this point showed that liver metastases had completely calcified without evidence of new disease ( Figure 1 ). With the goal of increasing tumor response, weekly paclitaxel was added to trastuzumab. Over 6 weeks, the CEA continued to trend down to 496